The enzyme at the center of the study, N-acetyltransferase 2, is one of the workhorses of so-called phase II xenobiotic metabolism, the cellular machinery that chemically modifies potentially harmful compounds so they can be excreted. NAT2 is famous among pharmacologists for its acetylation polymorphism: depending on which variants a person carries, they can be classified as rapid, intermediate, or slow acetylators. This classification matters because NAT2 does not simply detoxify dangerous molecules. In some cases, the enzyme performs the opposite trick, bioactivating inert procarcinogens — such as aromatic and heterocyclic amines found in tobacco smoke and in charred, well-cooked meat — into reactive intermediates that can bind DNA and initiate the mutations that drive cancer. Whether a given NAT2 variant raises or lowers cancer risk therefore depends on a delicate balance between detoxification and activation, and on which carcinogens a person actually encounters.

This biochemical ambiguity helps explain why decades of research on NAT2 and cancer have produced a thicket of conflicting results. In urinary bladder cancer, slow acetylator genotypes are relatively well established as risk factors, particularly among smokers, because slow acetylation allows aromatic amines to linger and undergo alternative activation pathways in the liver. For prostate cancer, however, the evidence has been far messier. Some studies, including work in Japanese and Bangladeshi populations, have reported associations between particular NAT2 variants and prostate tumors, while large meta-analyses have concluded that there is no overall link. Complicating matters further, NAT2 is one of the most geographically variable genes in the human genome, with acetylator frequencies differing dramatically between continents and even between neighboring populations, meaning that results from Europeans or East Asians cannot simply be assumed to hold elsewhere.

It was against this backdrop that Murtadha A. Tarish and Bassam K. Kudhair of the University of Kufa designed their case-control study. They enrolled 97 men with histologically confirmed prostate adenocarcinoma and 100 healthy controls, all drawn from an Iraqi Arab population, with samples and data collected through the Middle Euphrates Cancer Center in Najaf. Rather than relying on a small panel of pre-selected single nucleotide polymorphisms, the researchers amplified the NAT2 coding region using polymerase chain reaction and then read the sequence directly in both directions using Sanger sequencing. This approach allowed them to capture the actual constellation of variants carried by each participant, which is critical for NAT2 in particular, because the gene’s functional effects are determined not by single variants in isolation but by the specific combinations — haplotypes — that define the classical NAT2 alleles such as NAT25B and NAT26A.

Five polymorphisms emerged for analysis: c.282 C>T, c.341T>C, c.481 C>T, c.590G>A, and c.803G>A. These are the canonical sites used to infer acetylator status, and several of them have well-characterized functional consequences. The c.590G>A variant, for instance, corresponds to the rs1799930 SNP and produces an enzyme with markedly reduced stability and activity, while c.341T>C and c.481 C>T together define the slow-acetylator NAT2*5 lineage. When the researchers compared genotype frequencies between patients and controls, a consistent pattern appeared: variant genotypes generally trended toward a reduced risk of prostate cancer, an unexpected direction given that slow acetylation has often been cast as the risky configuration in other cancer types.

The strongest single-variant signal came from c.590G>A. Under an allelic model, the minor A allele was nominally associated with lower prostate cancer risk, with an odds ratio of 0.63 and a 95 percent confidence interval of 0.41 to 0.97, yielding a p-value of 0.036. When the researchers applied a correction for the multiple statistical tests performed — an essential safeguard in genetic association studies, where dozens of comparisons can easily generate false positives — the association was attenuated to a q-value of 0.108, just above the conventional significance threshold. A dominant model, comparing carriers of at least one A allele against non-carriers, produced a borderline protective estimate with an odds ratio of 0.59. In plain terms, men who carried the reduced-activity allele appeared roughly 40 percent less likely to have prostate cancer, but the result cannot yet be distinguished from statistical noise with confidence.

Because neighboring variants in a gene are often inherited together, the researchers next examined linkage disequilibrium, the non-random association of alleles along the chromosome. They found strong correlations between c.282 C>T and c.590G>A, and between c.341T>C and c.481 C>T, confirming that these sites travel as linked blocks in the Iraqi population, just as they do elsewhere. This structure allowed the team to reconstruct haplotypes and ask a more biologically meaningful question: does carrying an entire allele — a complete combination of variants that together determine enzyme phenotype — matter more than any single SNP? The answer was suggestive. The NAT2*6A haplotype, defined by the sequence motif TTCAA across the five sites, was nominally significantly associated with reduced prostate cancer risk, with an odds ratio of 0.34 and a p-value of 0.025. After multiple-testing correction, the q-value rose to 0.13, again falling short of strict significance. Combined genotype analysis pointed in the same direction, with carriers of variant alleles at both c.590G>A and c.803G>A showing a potential protective effect, at an odds ratio of 0.52, though this too was borderline.

The authors are appropriately cautious about these results, and their restraint is worth emphasizing. In a field plagued by underpowered studies and irreproducible associations, they explicitly state that the NAT2*6A finding did not survive correction for multiple testing and should be regarded as a possible association warranting validation in larger, independent cohorts. A sample of 97 cases and 100 controls is small by the standards of modern genetic epidemiology, and modest sample sizes inflate both the risk of false negatives and the volatility of odds ratio estimates. The population-specific design is both a strength and a limitation: it addresses a genuine gap, since Arab populations remain underrepresented in cancer genomics, but it also means the findings may not generalize, particularly given NAT2’s extraordinary global diversity, which has been shaped by local evolutionary pressures and demographic history.

Still, the biological logic of a protective effect is worth taking seriously. If NAT2 contributes to prostate carcinogenesis, the leading hypothesis involves heterocyclic aromatic amines, the mutagenic compounds that form when muscle meat is cooked at high temperatures. Laboratory work has shown that at least one prominent cooked-meat carcinogen can be metabolically activated within human prostate tissue itself, generating DNA adducts in the gland. Rapid acetylators, who convert procarcinogens more efficiently, might theoretically face higher exposure to reactive intermediates in prostate cells, whereas carriers of reduced-function alleles such as those defining NAT2*6A would activate less of the compound. The Iraqi results — in which reduced-function variants trended protective — are at least compatible with this model, though the authors note that whether NAT2-mediated bioactivation of procarcinogens actually contributes to prostate carcinogenesis remains to be established. Alternative explanations, including linkage to other nearby variants or confounding by diet, smoking, or age structure, cannot be excluded in a study of this size.

What the study ultimately delivers is a well-documented baseline for a population that has rarely appeared in this literature, together with a hypothesis precise enough to be tested. The next steps are clear: replicate the NAT2*6A association in larger Iraqi and broader Middle Eastern cohorts, ideally with direct measurement of acetylator phenotype rather than inference from genotype, and combine genetic data with dietary and smoking information to test whether gene–environment interactions, long suspected but rarely demonstrated for prostate cancer, are at work. Until then, the message for the public is one of restraint rather than alarm or reassurance. No NAT2 test can currently tell a man his prostate cancer risk, and the Iraqi findings, however intriguing, are a statistical whisper rather than a clinical signal. But as genomic medicine expands beyond its historical focus on European and East Asian populations, studies like this one illustrate why that expansion matters: the genetic architecture of cancer susceptibility may look different in Najaf than in Nagoya or Naples, and only local data can reveal the difference.

Subject of Research: Association between NAT2 gene polymorphisms and prostate cancer susceptibility in an Iraqi Arab population

Article Title: Analysis of NAT2 coding variants, combined genotypes, and haplotypes in prostate cancer susceptibility: a case-control study in an Iraqi Arab population

Article References: Tarish, M. A., & Kudhair, B. K. (2026). Analysis of NAT2 coding variants, combined genotypes, and haplotypes in prostate cancer susceptibility: a case-control study in an Iraqi Arab population. Molecular Biology Reports, 53(1), Article 1644. https://doi.org/10.1007/s11033-026-12859-8

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12859-8

Keywords: prostate cancer, NAT2, genetic polymorphism, haplotype, NAT2*6A, acetylator phenotype, xenobiotic metabolism, case-control study, Iraqi Arab population, rs1799930, cancer susceptibility, molecular epidemiology